Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated reported FY 2025 financial results with revenue of $12.1 million, representing the company's primary income source. The company incurred significant operating expenses totaling $116.7 million, comprising $94.3 million in research and development and $22.4 million in general and administrative costs. This resulted in a loss from operations of $104.6 million and a net loss of $99.5 million, with other income of $5.1 million partially offsetting operational losses. The company reported basic and diluted net loss per share of $1.00 based on 77.0 million weighted average common shares outstanding. Cash flow from operations was negative $56.3 million, while investing activities generated $53.5 million primarily from marketable securities transactions, and financing activities provided $24.8 million mainly from equity issuances. The balance sheet shows total assets of $141.3 million, including $105.7 million in current assets with $35.3 million in cash and equivalents and $68.0 million in marketable securities, against total liabilities of $72.7 million and stockholders' equity of $68.6 million.

Key Takeaways